Pharma Giants Sanofi, Johnson & Johnson Join Forces To Develop E.coli Vaccine
Portfolio Pulse from Vandana Singh
Sanofi SA (SNY) and Janssen Pharmaceuticals, a unit of Johnson & Johnson (JNJ), have partnered to develop and commercialize a vaccine for extraintestinal pathogenic E. coli. The vaccine is currently in Phase 3 trials. Sanofi will pay J&J’s Janssen unit $175 million upfront and development and commercial milestones. A profit-share arrangement will exist in the U.S., EU4, and the U.K.
October 03, 2023 | 12:25 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Janssen Pharmaceuticals, a unit of Johnson & Johnson, has partnered with Sanofi to develop an E. coli vaccine, receiving an upfront payment of $175 million.
The partnership with Sanofi and the upfront payment for the E. coli vaccine development could potentially boost J&J's revenues and strengthen its pharmaceutical portfolio.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Sanofi has entered into a partnership with Janssen Pharmaceuticals to develop an E. coli vaccine, committing to an upfront payment of $175 million.
The partnership with Janssen Pharmaceuticals and the commitment to the development of the E. coli vaccine could potentially boost Sanofi's portfolio and revenues in the future.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100